Literature DB >> 26204115

Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.

Seung Hyun Son1, Sang-Woo Lee1, Shin Young Jeong1, Bong-Il Song2, Yee Soo Chae3, Byeong-Cheol Ahn1, Jaetae Lee1.   

Abstract

OBJECTIVE: This study was performed to evaluate the prognostic relevance of PET parameters measured by (18)F-FDG PET/CT in patients with invasive ductal carcinoma of the breast (IDC) who had distant metastasis at the time of initial diagnosis.
MATERIALS AND METHODS: Forty women with IDC who had distant metastasis at the time of initial diagnosis and who underwent FDG PET/CT before receiving treatment were enrolled in the study. Clinicopathologic parameters and metabolic PET parameters, including the maximum standardized uptake value (SUVmax) of the primary tumor (pSUVmax), the SUVmax of the axillary lymph node (nSUVmax), the highest SUVmax of whole malignant lesions (wSUVmax), the whole-body (WB) metabolic tumor volume (MTV), and WB total lesion glycolysis (TLG), were analyzed to determine their usefulness in predicting overall survival (OS). Univariate and multivariate analyses were performed with the use of Kaplan-Meier and Cox proportional hazards models.
RESULTS: Twenty-one of the 40 patients (52.5%) died during follow-up (mean follow-up, 36.4 months; range, 0.8-71.4 months). Nonsurvivors had a statistically significantly higher mean (± SD) WB MTV than did survivors (424.0 ± 683.9 vs 92.1 ± 96.3 cm(3); p = 0.0430). T category, performance of palliative surgery, presence of visceral metastasis, wSUVmax, WB MTV, and WB TLG were identified by univariate analysis as prognostic factors for OS, whereas age, N category, hormone receptor status, status, triple-negative breast cancer status (defined as a tumor for which estrogen receptor, progesterone receptor, and ERBB2 statuses were all negative), pSUVmax, and nSUVmax were not. Multivariate analysis revealed that only WB MTV independently predicted OS (hazard ratio, 4.10; 95% CI, 1.17-14.31; p = 0.0280).
CONCLUSION: The WB MTV value, as determined by FDG PET/CT performed before treatment, was found to be an independent prognostic factor for OS in patients with IDC who had distant metastasis at the time of initial diagnosis.

Entities:  

Keywords:  18F-FDG PET/CT; metastatic breast cancer; whole-body metabolic tumor volume

Mesh:

Substances:

Year:  2015        PMID: 26204115     DOI: 10.2214/AJR.14.13906

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-14       Impact factor: 9.236

2.  Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.

Authors:  Xuee Zhu; Chuanhong Liao; Bill C Penney; Feng Li; Mark K Ferguson; Cassie A Simon; Tianming Wu; Haiyan Liu; Yonglin Pu
Journal:  Nucl Med Commun       Date:  2017-02       Impact factor: 1.690

3.  Assessment of Aggressiveness of Breast Cancer Using Simultaneous 18F-FDG-PET and DCE-MRI: Preliminary Observation.

Authors:  Nathaniel E Margolis; Linda Moy; Eric E Sigmund; Melanie Freed; Jason McKellop; Amy N Melsaether; Sungheon Gene Kim
Journal:  Clin Nucl Med       Date:  2016-08       Impact factor: 7.794

4.  18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer.

Authors:  Ana E Brito; Allan Santos; André Deeke Sasse; Cesar Cabello; Paulo Oliveira; Camila Mosci; Tiago Souza; Barbara Amorim; Mariana Lima; Celso D Ramos; Elba Etchebehere
Journal:  Oncotarget       Date:  2017-05-30

5.  Preoperative blood-routine markers and prognosis of esophageal squamous cell carcinoma: The Fujian prospective investigation of cancer (FIESTA) study.

Authors:  Dan Hu; Xiandong Lin; Yan Chen; Qing Chang; Gang Chen; Chao Li; Hejun Zhang; Zhaolei Cui; Binying Liang; Wenhui Jiang; Kaida Ji; Jun Huang; Feng Peng; Xiongwei Zheng; Wenquan Niu
Journal:  Oncotarget       Date:  2017-04-04

6.  Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis.

Authors:  Young-Sil An; Doo Kyoung Kang; Yongsik Jung; Tae Hee Kim
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

7.  Prognostic influence of 3-dimensional tumor volume on breast cancer compared to conventional 1-dimensional tumor size.

Authors:  Ki-Tae Hwang; Wonshik Han; Sang Mok Lee; Jaewoo Choi; Jongjin Kim; Jiyoung Rhu; Young A Kim; Dong-Young Noh
Journal:  Ann Surg Treat Res       Date:  2018-09-28       Impact factor: 1.859

8.  Prognostic Significance of Metabolic Parameters and Textural Features on 18F-FDG PET/CT in Invasive Ductal Carcinoma of Breast.

Authors:  Chin-Chuan Chang; Chao-Jung Chen; Wen-Ling Hsu; Shu-Min Chang; Ying-Fong Huang; Yu-Chang Tyan
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

9.  Prognostic value of metabolic parameters on 18F-fluorodeoxyglucose positron tomography/computed tomography in classical rectal adenocarcinoma.

Authors:  Byung Wook Choi; Sungmin Kang; Sung Uk Bae; Woon Kyung Jeong; Seong Kyu Baek; Bong-Il Song; Kyoung Sook Won; Hae Won Kim
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

10.  Prognostic Value of Dual-Time-Point 18F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures.

Authors:  Mohammad Naghavi-Behzad; Charlotte Bjerg Petersen; Marianne Vogsen; Poul-Erik Braad; Malene Grubbe Hildebrandt; Oke Gerke
Journal:  Diagnostics (Basel)       Date:  2020-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.